SCHEMBL10249356

SCHEMBL10249356

CCC(C)n1c(-c2ccncc2)nc2ccc(C)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 4/20 0.44
RORC P51449 5/20 0.41
BRD4 O60885 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NLRP3 Q96P20 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PDE2A O00408 1/20 0.37
TLR8 Q9NR97 1/20 0.36
USP2 O75604 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10252663 0.89 NLRP3 (0.47) AAK1RORCBRD4MEN1KMT2A
SCHEMBL175440 0.84 S1PR1 (0.46) AAK1RORCBRD4CYP11B1CYP11B2
SCHEMBL10252666 0.77 NLRP3 (0.58) AAK1RORCMEN1KMT2ACYP11B1
SCHEMBL169563 0.76 HTR2B (0.42) AAK1RORCMEN1KMT2AKDM4E
SCHEMBL10248874 0.75 MEN1 (0.66) AAK1MEN1KMT2ACYP11B1CYP11B2
SCHEMBL10249302 0.75 AAK1 (0.52) AAK1RORCMEN1KMT2ACYP11B1
SCHEMBL10249379 0.74 USP2 (0.52) AAK1RORCMEN1KMT2ACYP11B1
SCHEMBL10249414 0.74 NLRP3 (0.42) RORCMEN1KMT2ANLRP3KDM4E
SCHEMBL1104864 0.69 ALDH1A1 (0.54) MEN1KMT2ANLRP3KDM4EALDH1A1
SCHEMBL29411986 0.69 TP53 (0.62) RORCBRD4MEN1KMT2ACYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 AAK1 2483/4885RORC 1366/4885BRD4 513/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 AAK1 2483/4885RORC 1366/4885BRD4 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.